-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Benzinga·08/19/2026 13:31:11
语音播报
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.